Zacks Investment Research
21 Jul 2026, 16:46 UTC · 3h ago
Novartis Q2 Earnings & Revenues Top Estimates, Key Drugs Perform Well
NewsImpactScreener rates every claim in this story for market impact and maps it to the tickers most exposed.
Zacks Investment Research
21 Jul 2026, 16:46 UTC · 3h ago
NewsImpactScreener rates every claim in this story for market impact and maps it to the tickers most exposed.
What the story claims
4 claims · each scored for market impact
Novartis reported second-quarter core EPS of $2.41 and revenues of $14.4 billion, both of which beat Zacks Consensus Estimates. — Earnings and revenue beats typically drive short-term positive price action for the specific ticker.
+0.40Entresto sales nearly halved due to the onset of generic competition in the United States. — Significant revenue loss in a major product represents a long-term headwind to growth.
-0.30Key growth brands, including Kisqali (43%) and Kesimpta (32%), showed strong double-digit sales growth. — Strong performance in newer therapeutic areas demonstrates the company's ability to offset losses from generic competition.
+0.30Continue reading
6 related stories
Top 3 movers · tap to explore
Core net income decreased by 3% to $4.6 billion year-over-year. — A slight decline in net income suggests a plateau in profitability despite top-line revenue growth.
Which stocks this story touches
Reported Q2 core earnings and revenues that beat Zacks Consensus Estimates, with strong growth in key brands.
Free · No account
Get a free daily PDF briefing — the last 24 hours of news, with summaries and the market-impact score for each story, delivered an hour before the open.
We’ll watch
Pre-filled from this story — remove any you don’t want. Add more tickers & tags or fine-tune your watchlist anytime — every email has an edit link, no account needed.
Free forever · one email a day, max · unsubscribe in one click.How it works
How the impact breaks down
Where the story's weight lands
Stocks most exposed
Modeled from each name's sensitivity to this story
Zacks Investment Research
3h ago
